A detailed history of Tower Research Capital LLC (Trc) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,340 shares of NTLA stock, worth $90,662. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,340
Previous 41,973 84.9%
Holding current value
$90,662
Previous $939,000 86.16%
% of portfolio
0.0%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $702,682 - $974,918
-35,633 Reduced 84.9%
6,340 $130,000
Q2 2024

Aug 13, 2024

BUY
$20.02 - $27.22 $820,159 - $1.12 Million
40,967 Added 4072.27%
41,973 $939,000
Q1 2024

May 15, 2024

SELL
$23.82 - $32.8 $63,146 - $86,952
-2,651 Reduced 72.49%
1,006 $27,000
Q4 2023

Feb 13, 2024

BUY
$23.16 - $32.34 $486 - $679
21 Added 0.58%
3,657 $111,000
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $16,695 - $24,171
528 Added 16.99%
3,636 $114,000
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $92,847 - $123,590
-2,685 Reduced 46.35%
3,108 $126,000
Q1 2023

May 09, 2023

BUY
$33.3 - $44.82 $83,016 - $111,736
2,493 Added 75.55%
5,793 $216,000
Q4 2022

Feb 10, 2023

SELL
$33.21 - $62.69 $1.11 Million - $2.09 Million
-33,296 Reduced 90.98%
3,300 $115,000
Q3 2022

Nov 10, 2022

BUY
$53.92 - $71.7 $1.22 Million - $1.62 Million
22,567 Added 160.86%
36,596 $2.05 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $473,119 - $936,773
12,292 Added 707.66%
14,029 $726,000
Q1 2022

May 12, 2022

SELL
$58.27 - $118.99 $190,892 - $389,811
-3,276 Reduced 65.35%
1,737 $126,000
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $238,599 - $327,636
2,368 Added 89.53%
5,013 $592,000
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $19,987 - $26,693
-151 Reduced 5.4%
2,645 $355,000
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $2.7 Million - $7.19 Million
-44,382 Reduced 94.07%
2,796 $453,000
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $2.17 Million - $3.9 Million
46,598 Added 8034.14%
47,178 $3.79 Million
Q4 2020

Feb 16, 2021

SELL
$18.83 - $63.53 $103,452 - $349,033
-5,494 Reduced 90.45%
580 $32,000
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $43,115 - $61,527
2,468 Added 68.44%
6,074 $120,000
Q2 2020

Aug 13, 2020

BUY
$11.14 - $22.87 $40,003 - $82,126
3,591 Added 23940.0%
3,606 $76,000
Q1 2020

May 15, 2020

BUY
$9.44 - $15.58 $141 - $233
15 New
15 $0
Q4 2019

Feb 07, 2020

SELL
$10.43 - $17.67 $15,060 - $25,515
-1,444 Closed
0 $0
Q3 2019

Nov 05, 2019

SELL
$13.07 - $18.51 $99,776 - $141,305
-7,634 Reduced 84.09%
1,444 $19,000
Q2 2019

Aug 13, 2019

BUY
$13.88 - $18.41 $124,337 - $164,916
8,958 Added 7465.0%
9,078 $149,000
Q1 2019

May 14, 2019

BUY
$12.79 - $17.62 $1,534 - $2,114
120 New
120 $2,000
Q4 2018

Feb 14, 2019

SELL
$11.39 - $27.13 $27,894 - $66,441
-2,449 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$25.78 - $32.6 $63,135 - $79,837
2,449 New
2,449 $70,000
Q2 2018

Aug 15, 2018

SELL
$20.02 - $30.79 $37,617 - $57,854
-1,879 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$19.43 - $34.95 $36,508 - $65,671
1,879 New
1,879 $40,000
Q4 2017

Feb 09, 2018

SELL
$17.39 - $31.12 $48,796 - $87,322
-2,806 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$15.16 - $25.75 $42,538 - $72,254
2,806
2,806 $70,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.